Is Trulance Better Than Linzess For Constipation?

Neither Trulance nor Linzess is universally better. Both are prescription drugs approved by the FDA for chronic idiopathic constipation, and head-to-head trials comparing them directly are limited. The choice usually comes down to which drug a person tolerates and how their body responds.

Is Trulance Better Than Linzess For Constipation?

There is no clear winner. Trulance (plecanatide) and Linzess (linaclotide) belong to the same drug class and work through the same basic mechanism. Large trials show each one outperforms placebo for chronic constipation. What researchers have not done is run the kind of large, direct comparison that would let anyone say one is better than the other for most people.

Both drugs are approved for chronic idiopathic constipation, which means constipation with no identifiable cause. Linzess has additional FDA approval for irritable bowel syndrome with constipation (IBS-C), while Trulance is also approved for IBS-C and for a specific type of constipation caused by opioid pain medications. That difference in approved uses matters for some patients.

When two drugs work the same way and neither has been proven superior, the decision usually rests on tolerability, cost, and how a person responds. That is the honest picture.

How Do Trulance and Linzess Work?

Both drugs are synthetic versions of a natural human peptide. They mimic a substance your gut already makes, called guanylate cyclase-C agonists. When this peptide binds to receptors in the lining of the intestine, it triggers a chain of events that increases fluid secretion into the gut and speeds up movement.

More fluid in the intestine softens stool. Faster movement means less water gets reabsorbed before stool exits. The result is more frequent, easier bowel movements.

The key difference between the two drugs is structural. Trulance was designed to be more stable in the acidic environment of the stomach, which is why it can be taken once daily without the special timing some other drugs require. Linzess is also taken once daily. Both are oral capsules.

Because they act on the same receptor and produce the same downstream effect, their side effect profiles overlap heavily. Diarrhea is the most common complaint for both.

What Does the Evidence Show About Each Drug?

Each drug has been tested against placebo in large randomized trials. These trials generally show that both increase the number of complete spontaneous bowel movements per week compared with placebo. The improvements are real but modest on average, and individual results vary widely.

Some research suggests that the two drugs have similar efficacy. A head-to-head comparison published in a gastroenterology journal found comparable results for chronic constipation, though the study was not large enough to detect small differences. That is a limitation worth naming.

What we do not have is a large body of direct comparison data. Most of what we know comes from separate trials against placebo, not from trials pitting the drugs against each other. When you compare two drugs only through separate placebo trials, you cannot reliably say which is stronger.

Both drugs carry a boxed warning about serious dehydration from severe diarrhea, especially in children. Neither should be given to children under six years old, and they are not approved for pediatric use in most cases.

Side Effects: How Do They Compare?

Diarrhea is the headline side effect for both. In clinical trials, diarrhea was the most frequently reported adverse event for Trulance and Linzess alike. Rates vary by dose and by the condition being treated.

Other common side effects include:

• Gas and bloating
• Abdominal pain or cramping
• Headache
• Nausea

Most side effects are mild to moderate and often lessen with continued use, though not always. Some people cannot tolerate either drug because of diarrhea.

One practical difference: because the drugs are different molecules, some people who cannot tolerate one may tolerate the other. This is not something that can be predicted ahead of time. It is usually discovered by trying one and seeing how the body responds.

Severe diarrhea can lead to dehydration and low blood pressure. Anyone taking either drug who develops severe or persistent diarrhea should contact a healthcare provider.

Which One Should You Try First?

There is no evidence-based rule that says one should always be tried before the other. Clinical practice varies. Some clinicians start with one drug and switch if it does not work or causes intolerable side effects.

The FDA-approved uses may guide the decision. If a person has IBS-C, both drugs are approved. If a person has constipation caused by opioid pain medication, Trulance is specifically approved for that use while Linzess is not. If a person has chronic idiopathic constipation without IBS, both are approved.

Cost and insurance coverage often decide the first choice. Both drugs are brand-name medications, and coverage varies by plan. Some insurers require a prior authorization or step therapy before covering either one. Generic versions are not widely available in the US for either drug as of current prescribing information.

It is reasonable to ask a prescriber why one is being recommended over the other. If the answer is “insurance covers this one” or “I usually start here,” that is honest and common. If the answer claims one is proven stronger, that claim is not supported by current evidence.

What If Neither Drug Works?

Not everyone responds to these drugs. Some people get no benefit. Others get relief but cannot tolerate the diarrhea. When that happens, other options exist.

Other prescription options for chronic constipation include lubiprostone, which works through a different mechanism, and prucalopride, a drug that stimulates gut movement through a different receptor pathway. Each has its own side effect profile and approved uses.

Non-drug approaches remain important regardless of medication. Fiber, fluids, and physical activity help some people. So do over-the-counter osmotic laxatives like polyethylene glycol, which draw water into the stool. These are not replacements for prescription therapy in severe cases, but they are part of the broader picture.

If constipation is severe, persistent, or accompanied by warning signs like blood in the stool, unexplained weight loss, or a sudden change in bowel habits, that warrants medical evaluation. Those symptoms can signal something more serious than routine constipation.

Are There People Who Should Not Take Either Drug?

Both drugs are contraindicated in children under six years old because of the risk of severe dehydration from diarrhea. They are also contraindicated in people with a known blockage in the intestines, since stimulating gut movement when there is a physical obstruction can cause harm.

People with certain other bowel conditions should talk to a doctor before starting either drug. That includes anyone with a history of bowel surgery or a condition that affects the structure of the intestines.

Pregnancy and breastfeeding data are limited for both drugs. No clinical guidelines currently establish their safety in these populations. Anyone who is pregnant, planning to become pregnant, or breastfeeding should discuss risks and alternatives with a healthcare provider rather than starting either drug on their own.